Ginkgo Bioworks produces bacteria for industrial purposes and is currently leading the synthetic biology market. In September, Ginkgo Bioworks went public through a SPAC company with a DNA ticker.
Ginkgo shares were converted into shares of a new public company with a coefficient of 49.08x. In other words, the company implemented a stock split: the number of issued shares increased by 49.08 times, and their price decreased by 49.08 times.
A similar conversion has been implemented on the United Traders platform. In October 2020, when we first offered to invest in Ginkgo Bioworks, the price per share was $138.6. As a result of conversion, the price per share decreased to $2.82. When the company went public through SPAC, its shares were valued at $10. Thus, the return on investment at the pre-IPO stage to the company's exit point ($10) is 254%.
We'd like to remind you that for those, who invest at the pre-IPO stage, there is a lock-up period of 180 days after the placement date, expiring on March 16, 2022. After that, we will start transferring shares to our brokerage account.